Evidence map›Paper›PMID 28533689›Full record

ArticleJournal of asthma and allergy2017

Medication-related costs of rhinitis in Australia: a NostraData cross-sectional study of pharmacy purchases.

Pete Smith, David Price, Richard Harvey, Andrew Simon Carney, Vicky Kritikos, Sinthia Z Bosnic-Anticevich, Louise Christian, Derek Skinner, Victoria Carter, Alice Marie Sybille Durieux

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of asthma and allergy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 3 countries.

Pete SmithClinical Medicine, Griffith University, Southport, QLD, Australia.
David PriceObservational and Pragmatic Research Institute, Singapore.
Richard HarveyApplied Medical Research Center, University of New South Wales, Sydney, NSW, Australia.
Andrew Simon CarneyDepartment of Otolaryngology - Head and Neck Surgery, Flinders University, Adelaide, SA, Australia.
Vicky KritikosWoolcock Institute of Medical Research, University of Sydney, Sydney, NSW, Australia.
Sinthia Z Bosnic-AnticevichWoolcock Institute of Medical Research, University of Sydney, Sydney, NSW, Australia.
Louise ChristianNostraData, Kew, VIC, Australia.
Derek SkinnerOptimum Patient Care, Cambridge, UK.
Victoria CarterOptimum Patient Care, Cambridge, UK.
Alice Marie Sybille DurieuxCentre of Academic Primary Care, University of Aberdeen, Aberdeen, UK.
University of Aberdeen · GBFlinders University · AUGriffith University · AUSydney South West Area Health Service · AUThe University of Sydney · AUUNSW Sydney · AUVicRoads · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThere is a relative paucity of research regarding medication expenditure associated with multiple-therapy use for rhinitis in Australia. To describe 1) the nature and extent of multiple-therapy use for rhinitis in Australia using data on therapies purchased with prescription or over-the-counter (OTC) and 2) additional costs incurred by multiple-therapy use compared with intranasal corticosteroid (INCS) therapy alone. PATIENTS AND

methodsA retrospective observational study was carried out using a database containing anonymous pharmacy transaction data available from 20% of pharmacies in Australia that links doctor prescriptions and OTC purchase information. Pharmacy purchases of at least one prescription or OTC rhinitis treatment, with or without additional asthma/chronic obstructive pulmonary disease (COPD) therapy, by patients during 2013 and 2014 were assessed.

resultsIn total, 4,247,193 prescription and OTC rhinitis treatments were purchased from 909 pharmacies over 24 months. The majority of rhinitis therapy transactions were single-therapy purchases without additional asthma/COPD therapy. Of the single therapies purchased, 73% were oral antihistamines (OAHs) and 15% were INCS therapy. Dual-therapy purchases of INCSs and OAHs accounted for 40% of multiple-therapy purchases. Patients frequently purchased OAHs, nonsteroidal nasal sprays, and eye drops for allergic conjunctivitis alongside INCSs, resulting in higher financial costs (up to AU$21 per treatment episode) compared with INCS monotherapy.

conclusionThis study highlighted the significant burden posed on community pharmacy to address the needs of people with rhinitis symptoms, and the failure to translate the evidence that INCSs are the most effective monotherapy for moderate to severe and/or persistent rhinitis into clinical practice in light of the lack of evidence supporting combination of INCS and OAH therapy. Health care professional engagement, especially at the pharmacy level, will be extremely important if we wish to ensure that the purchase of rhinitis treatment is in accordance with guidelines and that their use is optimal.

Indexed as

community pharmacyintranasal corticosteroidsoral antihistaminesover-the-counterprescriptionrhinitistherapy

Identifiers

PMID28533689
PMCPMC5431691
OpenAlexW2613902198

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.